Growing collateral arteries on demand

Charles C. Oh, Jason D. Klein, Raymond Q. Migrino, Kent Thornburg

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Recent studies have significantly advanced our understanding of arteriogenesis, raising hope that therapies to increase collateral arterial formation may become important new tools in the treatment of ischemic disease. The most important initiating trigger for arteriogenesis is the marked increase in shear stress which is sensed by the endothelium and leads to characteristic changes. Intracellularly, it was shown that platelet endothelial cell adhesion molecule (PECAM-1) becomes tyrosine-phosphorylated in response to increased shear stress, suggesting a role as a possible mechanoreceptor for dynamic and continual monitoring of shear stress. The signal generated by PECAM-1 leads to the activation of the Rho pathway among others. More than 40 genes have been shown to have a shear stress responsive element. The Rho pathway is activated early and appears to be essential to the arteriogenic response as inhibiting it abolished the effect of fluid shear stress. Overexpression of a Rho pathway member, Actin-binding Rho protein (Abra), led to a 60% increase in collateral perfusion over simple femoral artery occlusion. A patent for the Abra gene has been filed recently. It may be a harbinger of a future where collateral arteries grown on demand may become an effective treatment for ischemic vascular disease.

    Original languageEnglish (US)
    Pages (from-to)189-198
    Number of pages10
    JournalRecent Patents on Cardiovascular Drug Discovery
    Volume6
    Issue number3
    StatePublished - Sep 2011

    Fingerprint

    CD31 Antigens
    Arteries
    Microfilament Proteins
    Mechanoreceptors
    Femoral Artery
    Vascular Diseases
    Genes
    Endothelium
    Tyrosine
    Perfusion
    Therapeutics

    Keywords

    • Arteriogenesis
    • Collateral artery
    • Mechanotransduction
    • Shear stress

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Pharmacology (medical)
    • Drug Discovery

    Cite this

    Growing collateral arteries on demand. / Oh, Charles C.; Klein, Jason D.; Migrino, Raymond Q.; Thornburg, Kent.

    In: Recent Patents on Cardiovascular Drug Discovery, Vol. 6, No. 3, 09.2011, p. 189-198.

    Research output: Contribution to journalArticle

    Oh, CC, Klein, JD, Migrino, RQ & Thornburg, K 2011, 'Growing collateral arteries on demand', Recent Patents on Cardiovascular Drug Discovery, vol. 6, no. 3, pp. 189-198.
    Oh, Charles C. ; Klein, Jason D. ; Migrino, Raymond Q. ; Thornburg, Kent. / Growing collateral arteries on demand. In: Recent Patents on Cardiovascular Drug Discovery. 2011 ; Vol. 6, No. 3. pp. 189-198.
    @article{5ca860aa0bcd45b599cb04990db9fce3,
    title = "Growing collateral arteries on demand",
    abstract = "Recent studies have significantly advanced our understanding of arteriogenesis, raising hope that therapies to increase collateral arterial formation may become important new tools in the treatment of ischemic disease. The most important initiating trigger for arteriogenesis is the marked increase in shear stress which is sensed by the endothelium and leads to characteristic changes. Intracellularly, it was shown that platelet endothelial cell adhesion molecule (PECAM-1) becomes tyrosine-phosphorylated in response to increased shear stress, suggesting a role as a possible mechanoreceptor for dynamic and continual monitoring of shear stress. The signal generated by PECAM-1 leads to the activation of the Rho pathway among others. More than 40 genes have been shown to have a shear stress responsive element. The Rho pathway is activated early and appears to be essential to the arteriogenic response as inhibiting it abolished the effect of fluid shear stress. Overexpression of a Rho pathway member, Actin-binding Rho protein (Abra), led to a 60{\%} increase in collateral perfusion over simple femoral artery occlusion. A patent for the Abra gene has been filed recently. It may be a harbinger of a future where collateral arteries grown on demand may become an effective treatment for ischemic vascular disease.",
    keywords = "Arteriogenesis, Collateral artery, Mechanotransduction, Shear stress",
    author = "Oh, {Charles C.} and Klein, {Jason D.} and Migrino, {Raymond Q.} and Kent Thornburg",
    year = "2011",
    month = "9",
    language = "English (US)",
    volume = "6",
    pages = "189--198",
    journal = "Recent Patents on Cardiovascular Drug Discovery",
    issn = "1574-8901",
    publisher = "Bentham Science Publishers B.V.",
    number = "3",

    }

    TY - JOUR

    T1 - Growing collateral arteries on demand

    AU - Oh, Charles C.

    AU - Klein, Jason D.

    AU - Migrino, Raymond Q.

    AU - Thornburg, Kent

    PY - 2011/9

    Y1 - 2011/9

    N2 - Recent studies have significantly advanced our understanding of arteriogenesis, raising hope that therapies to increase collateral arterial formation may become important new tools in the treatment of ischemic disease. The most important initiating trigger for arteriogenesis is the marked increase in shear stress which is sensed by the endothelium and leads to characteristic changes. Intracellularly, it was shown that platelet endothelial cell adhesion molecule (PECAM-1) becomes tyrosine-phosphorylated in response to increased shear stress, suggesting a role as a possible mechanoreceptor for dynamic and continual monitoring of shear stress. The signal generated by PECAM-1 leads to the activation of the Rho pathway among others. More than 40 genes have been shown to have a shear stress responsive element. The Rho pathway is activated early and appears to be essential to the arteriogenic response as inhibiting it abolished the effect of fluid shear stress. Overexpression of a Rho pathway member, Actin-binding Rho protein (Abra), led to a 60% increase in collateral perfusion over simple femoral artery occlusion. A patent for the Abra gene has been filed recently. It may be a harbinger of a future where collateral arteries grown on demand may become an effective treatment for ischemic vascular disease.

    AB - Recent studies have significantly advanced our understanding of arteriogenesis, raising hope that therapies to increase collateral arterial formation may become important new tools in the treatment of ischemic disease. The most important initiating trigger for arteriogenesis is the marked increase in shear stress which is sensed by the endothelium and leads to characteristic changes. Intracellularly, it was shown that platelet endothelial cell adhesion molecule (PECAM-1) becomes tyrosine-phosphorylated in response to increased shear stress, suggesting a role as a possible mechanoreceptor for dynamic and continual monitoring of shear stress. The signal generated by PECAM-1 leads to the activation of the Rho pathway among others. More than 40 genes have been shown to have a shear stress responsive element. The Rho pathway is activated early and appears to be essential to the arteriogenic response as inhibiting it abolished the effect of fluid shear stress. Overexpression of a Rho pathway member, Actin-binding Rho protein (Abra), led to a 60% increase in collateral perfusion over simple femoral artery occlusion. A patent for the Abra gene has been filed recently. It may be a harbinger of a future where collateral arteries grown on demand may become an effective treatment for ischemic vascular disease.

    KW - Arteriogenesis

    KW - Collateral artery

    KW - Mechanotransduction

    KW - Shear stress

    UR - http://www.scopus.com/inward/record.url?scp=80053546525&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=80053546525&partnerID=8YFLogxK

    M3 - Article

    C2 - 21861827

    AN - SCOPUS:80053546525

    VL - 6

    SP - 189

    EP - 198

    JO - Recent Patents on Cardiovascular Drug Discovery

    JF - Recent Patents on Cardiovascular Drug Discovery

    SN - 1574-8901

    IS - 3

    ER -